(Reuters) – AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.
The European conglomerate will commercialize the South Korean company’s copycat version of Herceptin. https://www.biopharmadive.com/news/mundipharma-inks-third-biosimilar-deal-with-celltrion/519580/
Biogen has reported record biosimilar revenues and says it intends to increase its share in Samsung Bioepis. https://www.biopharma-reporter.com/Article/2018/01/26/Biogen-looking-to-up-its-stake-in-Samsung-biosimilar-JV
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. http://www.worldpharmanews.com/novartis/4264-sandoz-announces-exclusive-global-collaboration-with-biocon-on-next-generation-biosimilars
Formycon and its commercialisation partner bioeq have positioned themselves for the potential launch of a Lucentis (ranibizumab) biosimilar in 2020. https://www.biopharma-reporter.com/Article/2017/11/28/Lucentis-biosimilar-Formycon-eyes-2020-for-US-launch
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives. After a financial deal was agreed with Amgen, it looks like the drug should have the immediate biosimilar threat removed from its path running up to the beginning of 2023.
read more http://www.pharmafile.com/news/515253/five-more-biosimilar-free-years-abbvie-s-humira
US regulators have approved Boehringer Ingelheim’s Cyltezo, a biosimilar to AbbVie’s Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases. http://www.pharmatimes.com/news/boehringers_humira_biosimilar_wins_us_green_light_1203707
Merck & Co. will challenge both reference drugmaker J&J and fellow biosimilar developer Pfizer through its version of Remicade, Renflexis. http://www.biopharma-reporter.com/Markets-Regulations/Merck-Co.-launches-US-Remicade-biosimilar-at-35-discount
MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology. Results of one study, which involved 544 RA patients, showed 33.1% treated with […] http://www.pm360online.com/biosimilar-immunogenicity-studies-produce-no-surprises/